Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 38, 2024 - Issue 12
152
Views
1
CrossRef citations to date
0
Altmetric
Research Articles

A new biphenanthrene with cytotoxic activity from Liparis nervosa (Thunb.) Lindl

, , , , , , & show all
Pages 2012-2018 | Received 23 Jan 2023, Accepted 01 Jul 2023, Published online: 03 Sep 2023
 

Abstract

2,7,2′-Trihydroxy-3,4,4′7′-tetramethoxy-1,1′-biphenanthrene (1), a previously undescribed biphenanthrene, and five known phenanthrenes, i.e. 2,5-dihydroxy-4-methoxy-9,10-dihydroxyphenanthrene (2), 2,4-dihydroxy −7-methoxy-9,10-dihydroxyphenanthrene (3), 7-hydroxy-2-methoxy-phenanthrene-1,4-dione (4), 7-hydroxy-2-methoxy-9,10-dihydro­phenanthrene-1,4-dione (5), and 4,4′,7,7′-tetrahydroxy-2,2′-dimethoxy-9,9′,10,10′-tetrahydro−1,1′-biphenanthrene (6) were isolated from the whole plant (stems, leaves, roots and fruits) of Liparis nervosa (Thunb.) Lindl., which is a medicinal plant of the genus Liparis in the Orchidaceae family. The structures of isolates were identified using spectroscopic methods, including NMR and mass spectrometry. Additionally, the cytotoxic potency of all the isolates against human lung cancer A549 cell line was evaluated by an MTT assay. All the isolated compounds showed cytotoxic activities with IC50 values in the range of 10.20 ± 0.81 to 42.41 ± 2.34 μM. The obtained data highlight the importance of L. nervosa as a source of natural lead compounds for cancer therapy.

GRAPHICAL ABSTRACT

Disclosure statement

No potential conflict of interest was reported by the authors.

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This research work was supported by the Qinglan Project of Jiangsu Province of China, the High-end Talents Supporting Project of Yangzhou University of China, and the National College Students’ innovation and entrepreneurship training program of China (202211117028Z).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.